Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Annovis Bio ( (ANVS) ) has shared an announcement.
On January 28, 2026, Annovis Bio, Inc. held a webinar, supported by a prepared presentation that was made available to participants and stakeholders. The event signaled an effort by the company to formally communicate information to the market via a structured public forum, though no additional operational or strategic details were disclosed in the announcement.
The most recent analyst rating on (ANVS) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Annovis Bio stock, see the ANVS Stock Forecast page.
Spark’s Take on ANVS Stock
According to Spark, TipRanks’ AI Analyst, ANVS is a Neutral.
The score is primarily held down by weak financial performance (pre-revenue, ongoing losses and cash burn) and a valuation profile dominated by negative earnings. Technicals are mixed (better longer-term trend but weaker near-term), and the recent $6M equity raise modestly helps funding runway while adding dilution risk.
To see Spark’s full report on ANVS stock, click here.
More about Annovis Bio
Average Trading Volume: 1,657,937
Technical Sentiment Signal: Sell
Current Market Cap: $78.45M
For an in-depth examination of ANVS stock, go to TipRanks’ Overview page.